“…Clinical trialists often grapple with the need to balance statistical power, ethical considerations, and control over the type I error rate. Zhu et al [11] propose an adaptive seamless design (ASD) in conjunction with response adaptive randomization (RAR) to address these challenges. This innovative approach demonstrates how it is possible to achieve efficient and ethical objectives while maintaining control over the type I error rate, a crucial aspect in clinical trials.…”